Proteasome inhibitors target processes related to tumor cell proliferation, cell death, and angiogenesis by modulating the expression of proteins, such as p53, Bcl-2, BAX, and NFκB pathway components [35]. The gene discussed is NFKB1; the disease is neoplasm.